Rat Recombinant GHR protein, His Tag (V2LY-0526-LY9404)

Go to compare Compare Online Inquiry
Request for COA
Datasheet Target Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host
HEK293 Cells
Protein Species
Rat
Tag
His Tag
Protein Construction
This product is Rat Recombinant GHR protein, His Tag consist of Amino Acid: 1-265 and predicts a molecular mass of 29.6 kDa.
Molecule Mass
29.6 kDa
Sequence
Amino Acid: 1-265
Species
Rat

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity
>95% as determined by SDS-PAGE
Endotoxin
Please contact us for more information.
Format
Lyophilized
Reconstitution
Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.
Buffer
Lyophilized from sterile Tirs, NaCl, Glycerol, EDTA
Preservative
None
Storage
Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
More Infomation

Target

Full Name
growth hormone receptor
Function
Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).

The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.

Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
Biological Process
Activation of Janus kinase activity Source: Ensembl
Cartilage development involved in endochondral bone morphogenesis Source: Ensembl
Cellular response to hormone stimulus Source: BHF-UCL
Cellular response to insulin stimulus Source: Ensembl
Cytokine-mediated signaling pathway Source: GO_Central
Endocytosis Source: UniProtKB-KW
Growth hormone receptor signaling pathway Source: BHF-UCL
Hormone-mediated signaling pathway Source: Ensembl
Hormone metabolic process Source: BHF-UCL
Insulin-like growth factor receptor signaling pathway Source: BHF-UCL
Negative regulation of neuron death Source: Ensembl
Positive regulation of cell differentiation Source: Ensembl
Positive regulation of MAP kinase activity Source: BHF-UCL
Positive regulation of multicellular organism growth Source: BHF-UCL
Positive regulation of peptidyl-tyrosine phosphorylation Source: BHF-UCL
Positive regulation of receptor signaling pathway via JAK-STAT Source: GO_Central
Positive regulation of tyrosine phosphorylation of STAT protein Source: BHF-UCL
Receptor internalization Source: BHF-UCL
Receptor signaling pathway via JAK-STAT Source: BHF-UCL
Regulation of multicellular organism growth Source: BHF-UCL
Response to cycloheximide Source: BHF-UCL
Response to estradiol Source: BHF-UCL
Response to food Source: Ensembl
Response to glucocorticoid Source: Ensembl
Response to interleukin-1 Source: Ensembl
Response to morphine Source: Ensembl
Taurine metabolic process Source: BHF-UCL
Cellular Location
Cell membrane. On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non-degradative pathway.
Isoform 2: Cell membrane. Remains fixed to the cell membrane and is not internalized.
Growth hormone-binding protein: Secreted. Complexed to a substantial fraction of circulating GH.
Involvement in disease
Laron syndrome (LARS):
A severe form of growth hormone insensitivity characterized by growth impairment, short stature, dysfunctional growth hormone receptor, and failure to generate insulin-like growth factor I in response to growth hormone.
Growth hormone insensitivity, partial (GHIP):
A disease characterized by partial resistance to growth hormone resulting in short stature. Short stature is defined by a standing height more than 2 standard deviations below the mean (or below the 2.5 percentile) for sex and chronological age, compared with a well-nourished, healthy, genetically relevant population.
Topology
Extracellular: 19-264
Helical: 265-288
Cytoplasmic: 289-638
PTM
The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding to the receptor probably due to a conformational change in GHR rendering the receptor inaccessible to ADAM17 (By similarity).
On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2.
On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiquitination is not sufficient for GHR internalization (By similarity).
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Rat Recombinant GHR protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.